Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

US biotech major Gilead Sciences (Nasdaq: GILD) today announced positive top-line results from the Phase III ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

The data show that a regimen based on Trodelvy and PD-1 inhibitor Keytruda (pembrolizumab) was better than Keytruda plus ...

Gilead Sciences announced significant results from a Phase 3 study of Trodelvy combined with Merck's Keytruda in treating ...

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...

Gilead Sciences (NasdaqGS:GILD) recently announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, ...

In some patients with advanced triple-negative breast cancer, Trodelvy plus Keytruda was associated with an improvement in disease progression.

Triple-negative breast cancer accounts for approximately 15% of all breast cancers and has a higher chance of recurrence.

Gilead Sciences said that it saw positive results from the phase 3 study of its Trodelvy therapy in combination with Merck's Keytruda in patients with inoperable locally advanced or metastatic ...

This news summary includes discussions on the legality of Obamacare's preventive care, health impacts of pollution in India, ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...